Monte Rosa Therapeutics, Inc. GLUE Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -345.2%-301pp | -43.8%— | —— | —— | —— | |
| Net margin | -302.6%-271pp | -31.2%— | —— | —— | —— | |
| EBITDA margin | -325.8%-289pp | -37.1%— | —— | —— | —— | |
| Free cash flow margin | -45.8%-23.5pp | -22.2%-102pp | 79.9%+66.5pp | 13.4%-5.7pp | 19.1%-31.2pp | |
| Returns | ||||||
| Return on equity | -32.6%-15.7pp | -16.9%— | —— | —— | —— | |
| Return on assets | -23%-14.3pp | -8.7%— | —— | —— | —— | |
| Return on invested capital | -46.4%+12.6pp | -59%— | —— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.1×-0.2× | 0.3×-0.2× | 0.5×0.0× | 0.5×0.0× | 0.5×+0.3× | |
| Liquidity | ||||||
| Current ratio | 9.5×+3.4× | 6.1×-0.4× | 6.5×-0.6× | 7.2×+1.5× | 5.6×+3.2× | |
| Quick ratio | 9.5×+3.4× | 6.1×-0.4× | 6.5×-0.6× | 7.2×+1.5× | 5.6×+3.2× | |
| Cash ratio | 2.3×+0.2× | 2×-1.4× | 3.4×+1.7× | 1.7×+0.3× | 1.3×-0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×-0.1× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Interest coverage | -9.8×-5.6× | -4.2×— | —— | —— | —— | |
| Per Share | ||||||
| Book value per share | $5.23+86.2% | $2.81-6.0% | $2.98-8.5% | $3.26-1.7% | $3.32+10.0% | |
| Valuation | ||||||
| Market capitalization | $1.32B+28.9% | $1.02B+123% | $457.64M+57.0% | $291.56M+2.2% | $285.41M-33.1% | |
| Enterprise value | $1.2B+28.5% | $930.35M+221% | $289.46M+10.0% | $263.26M+5.8% | $248.74M+1.6% | |
| Price / sales | 30.6×+22.4× | 8.3×+5.7× | 2.5×+0.9× | 1.6×-0.2× | 1.8×-3.8× | |
| Price / book | 2.5×-1.9× | 4.4×+2.5× | 1.9×+0.8× | 1.1×+0.1× | 1×-0.9× | |
| EV / sales | 27.8×+20.3× | 7.5×+5.9× | 1.6×+0.1× | 1.5×-0.1× | 1.6×-1.7× | |
| Free cash flow yield | -1.5%+1.2pp | -2.7%-34.4pp | 31.7%+23.5pp | 8.2%-2.5pp | 10.7%+1.8pp | |
| Earnings yield | -9.9%-6.1pp | -3.8%— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Monte Rosa Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Monte Rosa Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.